Diagnostic Accuracy of Alpha-Methylacyl-CoA Racemase Immunohistochemical Expression for the Diagnosis of Ovarian and Endometrial Clear Cell Carcinomas.
AMACR
Accuracy
Clear cell carcinoma
Endometrium
Immunohistochemistry
ovary
Journal
Iranian journal of pathology
ISSN: 1735-5303
Titre abrégé: Iran J Pathol
Pays: Iran
ID NLM: 101515128
Informations de publication
Date de publication:
2023
2023
Historique:
received:
06
07
2022
accepted:
16
11
2022
medline:
29
6
2023
pubmed:
29
6
2023
entrez:
29
6
2023
Statut:
ppublish
Résumé
Clear cell carcinoma (CCC) is an uncommon histopathologic subtype of ovarian and endometrial carcinoma. Due to the morphologic overlapping with other subtypes of ovarian and endometrial carcinomas, an accurate diagnosis is crucial. In this study, 31 cases of ovarian clear cell carcinoma (OCCC), 28 endometrial clear cell carcinoma (ECCC), and 80 non-CCC subtypes (33 high-grade serous carcinomas of the ovary, 2 low-grade serous carcinomas, 10 ovarian endometrioid, 3 serous carcinomas and 29 endometrioid carcinomas of the endometrium) were investigated for immunohistochemical expression of AMACR. Sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) for the distinction of OCCC and ECCC from other histopathologic subtypes were calculated. Positive AMACR staining was seen in 18 OCCCs (58%) and 10 ECCCs (35.7%). In the non-clear cell group, 44 cases of ovarian (98%) and 25 cases of endometrial carcinoma (78%) showed negative results. Only one case of ovarian endometrioid carcinoma and 7 cases (22%) of endometrial endometrioid carcinomas revealed a positive reaction ( AMACR may be a highly specific immunohistochemical marker for the distinction of serous and clear cell carcinoma. A small percentage of endometrioid carcinoma may show positive staining. The sensitivity of this marker may not be higher than the other well-known Napsin-A IHC marker.
Sections du résumé
Background & Objective
UNASSIGNED
Clear cell carcinoma (CCC) is an uncommon histopathologic subtype of ovarian and endometrial carcinoma. Due to the morphologic overlapping with other subtypes of ovarian and endometrial carcinomas, an accurate diagnosis is crucial.
Methods
UNASSIGNED
In this study, 31 cases of ovarian clear cell carcinoma (OCCC), 28 endometrial clear cell carcinoma (ECCC), and 80 non-CCC subtypes (33 high-grade serous carcinomas of the ovary, 2 low-grade serous carcinomas, 10 ovarian endometrioid, 3 serous carcinomas and 29 endometrioid carcinomas of the endometrium) were investigated for immunohistochemical expression of AMACR. Sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) for the distinction of OCCC and ECCC from other histopathologic subtypes were calculated.
Results
UNASSIGNED
Positive AMACR staining was seen in 18 OCCCs (58%) and 10 ECCCs (35.7%). In the non-clear cell group, 44 cases of ovarian (98%) and 25 cases of endometrial carcinoma (78%) showed negative results. Only one case of ovarian endometrioid carcinoma and 7 cases (22%) of endometrial endometrioid carcinomas revealed a positive reaction (
Conclusion
UNASSIGNED
AMACR may be a highly specific immunohistochemical marker for the distinction of serous and clear cell carcinoma. A small percentage of endometrioid carcinoma may show positive staining. The sensitivity of this marker may not be higher than the other well-known Napsin-A IHC marker.
Identifiants
pubmed: 37383161
doi: 10.30699/IJP.2023.556417.2925
pmc: PMC10293609
doi:
Types de publication
Journal Article
Langues
eng
Pagination
57-63Déclaration de conflit d'intérêts
There is no conflict of interest to be disclosed.
Références
Pathology. 2006 Oct;38(5):426-32
pubmed: 17008281
Mod Pathol. 2006 Jan;19(1):83-9
pubmed: 16258507
Gynecol Oncol. 2021 Sep;162(3):741-750
pubmed: 34247767
Prog Lipid Res. 2013 Apr;52(2):220-30
pubmed: 23376124
APMIS. 2018 Jan;126(1):45-55
pubmed: 29266433
Pathology. 2015 Feb;47(2):105-11
pubmed: 25551297
J Microsc Ultrastruct. 2015 Apr-Jun;3(2):68-74
pubmed: 30023184
J Cancer. 2021 Feb 22;12(8):2295-2316
pubmed: 33758607
Appl Immunohistochem Mol Morphol. 2020 Sep;28(8):593-601
pubmed: 31361605
J Clin Pathol. 2003 Dec;56(12):892-7
pubmed: 14645345
Appl Immunohistochem Mol Morphol. 2012 Dec;20(6):580-7
pubmed: 22495362
Hum Pathol. 2006 Jun;37(6):698-703
pubmed: 16733210
Surg Pathol Clin. 2019 Jun;12(2):529-564
pubmed: 31097114
Chin Clin Oncol. 2020 Aug;9(4):47
pubmed: 32648448
Am J Surg Pathol. 2014 Feb;38(2):189-96
pubmed: 24145649
Tunis Med. 2010 Sep;88(9):651-4
pubmed: 20812179
Hum Pathol. 2013 Dec;44(12):2814-21
pubmed: 24119561
Am J Surg Pathol. 2013 Jun;37(6):874-81
pubmed: 23629444
Am J Pathol. 2003 Dec;163(6):2503-12
pubmed: 14633622
Histopathology. 2013 Jan;62(1):89-110
pubmed: 23240672
Am J Surg Pathol. 2012 Aug;36(8):1107-18
pubmed: 22790851
Iran J Pathol. 2020 Spring;15(2):81-85
pubmed: 32215023
Int J Gynecol Pathol. 2015 Jul;34(4):323-33
pubmed: 25851704
Pathol Res Pract. 2022 Aug;236:153953
pubmed: 35696768
Hum Pathol. 2007 Jul;38(7):1074-1080
pubmed: 17442376
Am J Surg Pathol. 2004 Jan;28(1):69-76
pubmed: 14707866
BMC Cancer. 2013 Nov 05;13:524
pubmed: 24191930
Hum Pathol. 2015 Jul;46(7):957-62
pubmed: 25971546